Ava M. Puccio

Ava M. Puccio

Auto-generated profile, based on publicly available information

Ava M. Puccio

Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Radiology
Verified
Journal Article
Closed access
MPMatthew Pease
Matthew Pease
DADooman Arefan
Dooman Arefan
JBJason Barber
Jason Barber
EYEsther Yuh
Esther Yuh
APAva Puccio
Ava Puccio
JYJohn K. Yue
John K. Yue
Deep learning prognostic models using both admission CT scans and clinical information can predict 6-month mortality and unfavorable outcomes after severe traumatic brain injury and outperformed th... Background After severe traumatic brain injury (sTBI), physicians use long-term prognostication to guide acute clinical care yet struggle to predict outcomes in comatose patients. Purpose To develo...

1 April 2009 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
APAva M. Puccio
Ava M. Puccio
MFMichael R. Fischer
Michael R. Fischer
BJBrian T. Jankowitz
Brian T. Jankowitz
HYHoward Yonas
Howard Yonas
JDJoseph M. Darby
Joseph M. Darby
DODavid O. Okonkwo
David O. Okonkwo

23 October 2019 in Journal of Neurotrauma
Verified
Journal Article
Closed access
TWTiffany E. Wilkins
Tiffany E. Wilkins
SBSue R. Beers
Sue R. Beers
ABAllison J. Borrasso
Allison J. Borrasso
JBJordan Brooks
Jordan Brooks
MMMatthew Mesley
Matthew Mesley
APAva M. Puccio
Ava M. Puccio
Favorable long-term functional outcomes after severe traumatic brain injury (TBI) may be underestimated. We analyzed 24-month functional outcomes from a consecutive series of severe TBI survivors. A prospective, observational database of severe TBI survivors from a single institution was analyzed. Glasgow Outcome Scale-Extended (GOS-E) scores were obtained at 3, 6, 12, and 24 months post-injury. GOS-E scores were dichotomized into unfavorable and favorable outcomes, and the proportion of survivors changing from unfavorable to favorable outcomes was calculated using Wilcoxon signed-rank tests. Surviving adults ( N = 304; mean age ± standard deviation = 35.06 ± 15.11; 80.92% male; mode of initial GCS = 7) were analyzed. A statistically significant mean increase in GOS-E was noted from 3 to 6, 6 to 12, 12 to 24, and 6 to 24 months after injury (0.65 [ p < 0.0001], 0.42 [ p < 0.0001], 0.23 [ p = 0.020], and 0.61 [ p < 0.0001], respectively). Moreover, 43% of survivors from 3 to 6 months, 36% from 6 to 12 months, 38% from 12 to 24 months, and 54% from 6 to 24 months progressed from an unfavorable to a favorable outcome. Two thirds of survivors in the unfavorable category at 3 months had favorable outcomes at 2 years. Overall, 74% of surviving adults with a documented GOS-E at 2 years after injury had a favorable outcome. Severe TBI survivors demonstrated significant improvement in functional outcomes from 3 to 24 months after injury. At 2 years, three fourths of survivors had a favorable outcome. Long-term prognosis in severe TBI is better than broadly appreciated.

1 October 2016 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
ENEnyinna L. Nwachuku
Enyinna L. Nwachuku
APAva M. Puccio
Ava M. Puccio
AAAdeolu Adeboye
Adeolu Adeboye
YCYue-Fang Chang
Yue-Fang Chang
JKJinho Kim
Jinho Kim
DODavid O. Okonkwo
David O. Okonkwo

1 April 2021 in Journal of Neurotrauma
Verified
Journal Article
Closed access
LXLinda B. Xu
Linda B. Xu
John K YueJohn K Yue
John K Yue
FKFrederick Korley
Frederick Korley
APAva M. Puccio
Ava M. Puccio
EYEsther L. Yuh
Esther L. Yuh
RDRamon Diaz-Arrastia
Ramon Diaz-Arrastia
Systemic inflammation impacts outcome after traumatic brain injury (TBI), but most TBI biomarker studies have focused on brain-specific proteins. C-reactive protein (CRP) is a widely used biomarker of inflammation with potential as a prognostic biomarker after TBI. The Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study prospectively enrolled TBI patients within 24 h of injury, as well as orthopedic injury and uninjured controls; biospecimens were collected at enrollment. A subset of hospitalized participants had blood collected on day 3, day 5, and 2 weeks. High-sensitivity CRP (hsCRP) and glial fibrillary acidic protein (GFAP) were measured. Receiver operating characteristic analysis was used to evaluate the prognostic ability of hsCRP for 6-month outcome, using the Glasgow Outcome Scale-Extended (GOSE). We included 1206 TBI subjects, 122 orthopedic trauma controls (OTCs), and 209 healthy controls (HCs). Longitudinal biomarker sampling was performed in 254 hospitalized TBI subjects and 19 OTCs. hsCRP rose between days 1 and 5 for TBI and OTC subjects, and fell by 2 weeks, but remained elevated compared with HCs (p < 0.001). Longitudinally, hsCRP was significantly higher in the first 2 weeks for subjects with death/severe disability (GOSE <5) compared with those with moderate disability/good recovery (GOSE ≥5); AUC was highest at 2 weeks (AUC = 0.892). Combining hsCRP and GFAP at 2 weeks produced AUC = 0.939 for prediction of disability. Serum hsCRP measured within 2 weeks of TBI is a prognostic biomarker for disability 6 months later. hsCRP may have utility as a biomarker of target engagement for anti-inflammatory therapies.

Verified
Journal Article
Open access
PDF file
NONicole (Nico) Osier
Nicole (Nico) Osier
EMEmily McGreevy
Emily McGreevy
LPLan Pham
Lan Pham
APAva Puccio
Ava Puccio
DRDianxu Ren
Dianxu Ren
CDC. Edward Dixon
C. Edward Dixon
Melatonin (MEL) is a hormone that is produced in the brain and is known to bind to MEL-specific receptors on neuronal membranes in several brain regions. MEL’s documented neuroprotective properties, low toxicity, and ability to cross the blood-brain-barrier have led to its evaluation for patients with traumatic brain injury (TBI), a condition for which there are currently no Food and Drug Administration (FDA)-approved therapies. The purpose of this manuscript is to summarize the evidence surrounding the use of melatonin after TBI, as well as identify existing gaps and future directions. To address this aim, a search of the literature was conducted using Pubmed, Google Scholar, and the Cochrane Database. In total, 239 unique articles were screened, and the 22 preclinical studies that met the a priori inclusion/exclusion criteria were summarized, including the study aims, sample (size, groups, species, strain, sex, age/weight), TBI model, therapeutic details (preparation, dose, route, duration), key findings, and conclusions. The evidence from these 22 studies was analyzed to draw comparisons across studies, identify remaining gaps, and suggest future directions. Taken together, the published evidence suggests that MEL has neuroprotective properties via a number of mechanisms with few toxic effects reported. Notably, available evidence is largely based on data from adult male rats and, to a lesser extent, mice. Few studies collected data beyond a few days of the initial injury, necessitating additional longer-term studies. Other future directions include diversification of samples to include female animals, pediatric and geriatric animals, and transgenic strains.